MicroRNA-433 Targets AKT3 and Inhibits Cell Proliferation and Viability in Breast Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Mar 21

PMID 29556282

Citations 24

Authors

Xiaolei Hu

Jie Wang

Wan He

Pan Zhao

Changsheng Ye

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the most frequently diagnosed malignancy in women. However, the molecular mechanisms underlying breast cancer pathogenesis are not fully understood. The present study examined the role of miR-433 in breast cancer and investigated its underlying molecular mechanisms of action. Reverse transcription-quantitative polymerase chain reaction and western blot analysis were performed to analyze the level of microRNA (miRNA/miR)/mRNA and protein expression, respectively. Additionally, MTT assay was used to determined cell proliferation and viability. Cell apoptosis was measured by flow cytometry. A dual-luciferase reporter assay was used to confirm the identity of the downstream target of miR-433. The results revealed that miR-433 was downregulated in breast cancer tissues and cell lines. Overexpression of miR-433 inhibited cell proliferation and cell viability in BT-549 cells, whereas downregulation of miR-433 increased cell proliferation and cell viability in MDA-MB-231 cells. Further flow cytometry analysis revealed that miR-433 was able to induce apoptosis and also alter the levels of proteins expression of B-cell lymphoma-2 and Bcl-associated X. Bioinformatics analysis showed that RAC-γ serine/threonine-protein kinase (AKT3) was one of the downstream targets of miR-433, and luciferase reporter assay further confirmed that AKT3 is a direct target of miR-433. The knockdown of AKT3 was able to inhibit proliferation and viability in BT-549 cells. Overexpression of AKT3 prevented the inhibitory effects of miR-433 on proliferation and viability in BT-549 cells. The level of AKT3 mRNA expression was upregulated in breast cancer tissues compared with normal tissues and was inversely correlated with miR-433 expression levels. In summary, the results of the present study results indicate that the tumor-suppressive role of miR-433 may be mediated by regulating AKT3. miR-433 may therefore serve as a potential therapeutic target for breast cancer.

Citing Articles

Differential miRNA and Protein Expression Reveals miR-1285, Its Targets TGM2 and CDH-1, as Well as CD166 and S100A13 as Potential New Biomarkers in Patients with Diabetes Mellitus and Pancreatic Adenocarcinoma.

Kolokotronis T, Majchrzak-Stiller B, Buchholz M, Mense V, Strotmann J, Peters I Cancers (Basel). 2024; 16(15).

PMID: 39123454 PMC: 11311671. DOI: 10.3390/cancers16152726.

Cellular and Exosomal MicroRNAs: Emerging Clinical Relevance as Targets for Breast Cancer Diagnosis and Prognosis.

Zablon F, Desai P, Dellinger K, Aravamudhan S Adv Biol (Weinh). 2024; 8(4):e2300532.

PMID: 38258348 PMC: 11198028. DOI: 10.1002/adbi.202300532.

The Multifunctional Nature of the MicroRNA/AKT3 Regulatory Axis in Human Cancers.

Yang C, Hardy P Cells. 2023; 12(22).

PMID: 37998329 PMC: 10670075. DOI: 10.3390/cells12222594.

Combinatorial Effects of miRNAs in HSV-2 Infection of Macrophages: An In Silico and In Vitro Integration Approach.

Banerjee A, Dass D, Dhotre K, Wakchoure P, More A, Rana S Vaccines (Basel). 2023; 11(9).

PMID: 37766164 PMC: 10537408. DOI: 10.3390/vaccines11091488.

Evidence and Metabolic Implications for a New Non-Canonical Role of Cu-Zn Superoxide Dismutase.

Sun Z, Lei X Int J Mol Sci. 2023; 24(4).

PMID: 36834640 PMC: 9966940. DOI: 10.3390/ijms24043230.

References

Pinweha P, Rattanapornsompong K, Charoensawan V, Jitrapakdee S . MicroRNAs and oncogenic transcriptional regulatory networks controlling metabolic reprogramming in cancers. Comput Struct Biotechnol J. 2016; 14:223-33. PMC: 4915959. DOI: 10.1016/j.csbj.2016.05.005. View

Leung A . The Whereabouts of microRNA Actions: Cytoplasm and Beyond. Trends Cell Biol. 2015; 25(10):601-610. PMC: 4610250. DOI: 10.1016/j.tcb.2015.07.005. View

Zhu Y, Liang Z, Li S, Xu X, Wang X, Wu J . c-Met and CREB1 are involved in miR-433-mediated inhibition of the epithelial-mesenchymal transition in bladder cancer by regulating Akt/GSK-3β/Snail signaling. Cell Death Dis. 2016; 7:e2088. PMC: 4849142. DOI: 10.1038/cddis.2015.274. View

Waugh M . Amplification of Chromosome 1q Genes Encoding the Phosphoinositide Signalling Enzymes PI4KB, AKT3, PIP5K1A and PI3KC2B in Breast Cancer. J Cancer. 2014; 5(9):790-6. PMC: 4216804. DOI: 10.7150/jca.9794. View

Sultana A, Idress R, Naqvi Z, Azam I, Khan S, Siddiqui A . Expression of the Androgen Receptor, pAkt, and pPTEN in Breast Cancer and Their Potential in Prognostication. Transl Oncol. 2014; . PMC: 4145356. DOI: 10.1016/j.tranon.2014.04.004. View

Dillon R, Muller W . Distinct biological roles for the akt family in mammary tumor progression. Cancer Res. 2010; 70(11):4260-4. PMC: 2880222. DOI: 10.1158/0008-5472.CAN-10-0266. View

Li X, Yang L, Shuai T, Piao T, Wang R . MiR-433 inhibits retinoblastoma malignancy by suppressing Notch1 and PAX6 expression. Biomed Pharmacother. 2016; 82:247-55. DOI: 10.1016/j.biopha.2016.05.003. View

Tzanninis I, Kotteas E, Ntanasis-Stathopoulos I, Kontogianni P, Fotopoulos G . Management and Outcomes in Metaplastic Breast Cancer. Clin Breast Cancer. 2016; 16(6):437-443. DOI: 10.1016/j.clbc.2016.06.002. View

Weiner-Gorzel K, Dempsey E, Milewska M, McGoldrick A, Toh V, Walsh A . Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells. Cancer Med. 2015; 4(5):745-58. PMC: 4430267. DOI: 10.1002/cam4.409. View

10.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

11.

Srivastava S, Reid B, Ghosh S, Kramer B . Research Needs for Understanding the Biology of Overdiagnosis in Cancer Screening. J Cell Physiol. 2015; 231(9):1870-5. PMC: 5811189. DOI: 10.1002/jcp.25227. View

12.

Mosquera J, Varma S, Pauli C, MacDonald T, Yashinskie J, Varga Z . MAGI3-AKT3 fusion in breast cancer amended. Nature. 2015; 520(7547):E11-2. DOI: 10.1038/nature14265. View

13.

Hemmatzadeh M, Mohammadi H, Jadidi-Niaragh F, Asghari F, Yousefi M . The role of oncomirs in the pathogenesis and treatment of breast cancer. Biomed Pharmacother. 2016; 78:129-139. DOI: 10.1016/j.biopha.2016.01.026. View

14.

Sonnenblick A, Ponde N, Piccart M . Metastatic breast cancer: The Odyssey of personalization. Mol Oncol. 2016; 10(8):1147-59. PMC: 5423195. DOI: 10.1016/j.molonc.2016.07.002. View

15.

Del Vescovo V, Meier T, Inga A, Denti M, Borlak J . A cross-platform comparison of affymetrix and Agilent microarrays reveals discordant miRNA expression in lung tumors of c-Raf transgenic mice. PLoS One. 2013; 8(11):e78870. PMC: 3827083. DOI: 10.1371/journal.pone.0078870. View

16.

Li C, Yang L, Zhang D, Jiang W . Systematic review and meta-analysis suggest that dietary cholesterol intake increases risk of breast cancer. Nutr Res. 2016; 36(7):627-35. DOI: 10.1016/j.nutres.2016.04.009. View

17.

Rudolph A, Chang-Claude J, Schmidt M . Gene-environment interaction and risk of breast cancer. Br J Cancer. 2016; 114(2):125-33. PMC: 4815812. DOI: 10.1038/bjc.2015.439. View

18.

Chin Y, Yoshida T, Marusyk A, Beck A, Polyak K, Toker A . Targeting Akt3 signaling in triple-negative breast cancer. Cancer Res. 2013; 74(3):964-73. PMC: 3946502. DOI: 10.1158/0008-5472.CAN-13-2175. View

19.

OHurley G, Daly E, OGrady A, Cummins R, Quinn C, Flanagan L . Investigation of molecular alterations of AKT-3 in triple-negative breast cancer. Histopathology. 2013; 64(5):660-70. DOI: 10.1111/his.12313. View

20.

Chin Y, Toker A . Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell Signal. 2008; 21(4):470-6. PMC: 2719559. DOI: 10.1016/j.cellsig.2008.11.015. View